PFE Stock Price Today (April 2026) — Pfizer Inc. Analysis & Key Metrics 2026-04-15
Pfizer Inc. (PFE) is trading at $27.22, up 0.41% today (as of April 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $28.58 (5.0% upside).
- Volatility remains elevated (20.79% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-1.20% YoY) alongside significant competitive pressures.
PFE Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Pfizer Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $215.39B
P/E Ratio
Forward P/E: 10.03
Revenue Growth
Year over Year
Analyst Target
+5.0% upside potential
Key Investor Questions About PFE
What investors need to know before buying
Based on current market data, PFE presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 47.19)
- Fundamentals say: Challenging (declining revenue trends)
PFE's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PFE investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $67.65B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, PFE stock traded between $20.92 and $28.75—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.79% annualized volatility and β=0.41, the stock exhibits low sensitivity to market moves—making PFE suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
QSM Asset Management Loads Up 611,000 Mobileye Shares
Mobileye develops advanced driver assistance and autonomous driving technologies for global automotive manufacturers and suppliers.
Top Stock Reports for NVIDIA, Apple & Coca-Cola
NVIDIA rides AI-driven demand and data center growth, but supply constraints, rising costs and competition threaten its ability to fully capitalize on momentum.
A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound?
Robert Half Inc. provides staffing and risk consulting solutions globally to employers across diverse industries.
What to Look for Before Buying a Pharma Stock
Start with the drug pipeline when researching pharma stocks to own.
QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup
ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries.
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings
PFE's non-oncology portfolio is in focus ahead of Q1, with Eliquis and Prevnar gains expected to be offset by declines in Comirnaty, Paxlovid and some specialty drugs
UBS Adjusts Pharma Outlook, Increases Pfizer (PFE) Price Target
Pfizer Inc. (NYSE:PFE) is included among the 14 Value Stocks with Highest Dividends. On April 13, UBS Group AG raised its price recommendation on Pfizer Inc. (NYSE:PFE) to $27 from $25. It maintained a Neutral rating on the shares. The update came as part of the firm’s Q1 preview for the pharmaceuticals and biotechnology group, […]
Telix Expands Board As Valuation And Momentum Draw Investor Attention
Telix Pharmaceuticals (ASX:TLX) has expanded its Board with the appointment of Dr. Maria Rivas and William Jellison as non executive directors. Dr. Rivas brings senior experience from Pfizer and prior public company board roles. Jellison adds corporate finance expertise from his tenure as CFO at Stryker Corporation. These changes follow the recent addition of David Gill, who is expected to become Chair, as part of a broader succession and governance plan. For readers tracking ASX:TLX, the...
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
The FDA grants priority review to Merck and Daiichi's BLA for ifinatamab deruxtecan to treat extensive-stage small cell lung cancer.
Earnings Preview: What to Expect From Pfizer’s Report
Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low double-digit range.
Frequently Asked Questions
Common investor questions about Pfizer Inc.
Pfizer Inc. (PFE) is currently trading at $27.22. The RSI (14-day) is at 47.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $28.58 implies 5.0% upside from current levels. Volatility is moderate at 20.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Pfizer Inc. (PFE): The trailing P/E ratio is 20.82, which is in line with broader market averages. The forward P/E is 10.03, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 13.77, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 1.86. Price-to-Sales is 2.57. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering PFE, the consensus price target is $28.58. This represents a 5.0% upside from the current price of $27.22. The range spans from a low target of $25.00 to a high target of $36.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Pfizer Inc. (PFE) pays a dividend with a current yield of approximately 6.32%. The annualized dividend rate is $1.72 per share. The payout ratio is 126.5%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-01-23.
Key risks for Pfizer Inc. (PFE) investors include: 1. Declining revenue (-1.2% YoY), indicating potential business headwinds. 2. Unsustainable dividend payout ratio (126%) could lead to a dividend cut. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Pfizer Inc.'s (PFE) current debt and financial health profile: Total debt stands at $67.65B. The debt-to-equity ratio is 77.96, which is moderate and generally manageable for most companies. The current ratio is 1.16, indicating adequate short-term liquidity. The quick ratio is 0.80. The company holds $13.60B in cash and equivalents. Free cash flow is positive at $13.43B, providing a cushion for debt servicing and shareholder returns.